To receive our complimentary newsletters please copy and paste http://www.emergingmarketsllc.com in to your web browser. On the upper right hand corner of the homepage enter your email address and click sign up. You will receive a confirmation email, click the link and your free subscription will be active.
InterMune, Inc. closed at $18.43 up $5.05 (37.74%) with volume of 6,119,345 InterMune, Inc. (Nasdaq: ITMN - News) yesterday provided an update on the progress of its Phase 1b multiple-ascending-dose (MAD) clinical trial evaluating ITMN-191 (R7227) as monotherapy in patients with chronic hepatitis C virus (HCV) infection. ITMN-191 is an HCV protease inhibitor in development by InterMune and its partner, Roche.
About InterMune, Inc.
InterMune, Inc., a biotechnology company, focuses on the development and commercialization of therapies in pulmonology and hepatology. It offers Actimmune for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis in the United States. The company also develops Pirfenidone, which is in phase III clinical status for the treatment of idiopathic pulmonary fibrosis; interferon gamma products that are in preclinical stage; and Protease Inhibitor program, which is in phase I clinical stage for the treatment of hepatitis c virus infections. In addition, the company, through its subsidiary, develops Infergen for the treatment of patients with liver disease who have chronic HCV infections. It has license and collaboration agreements with Hoffmann-LaRoche, Inc. and F.Hoffmann-La Roche, Ltd.; Genentech, Inc.; Boehringer Ingelheim International GmbH; Connetics Corporation; Marnac, Inc.; Array BioPharma, Inc.; Novartis Corporation; Shearwater Corporation; Maxygen Holdings, Ltd.; and Eli Lilly & Company. The company was founded in 1998 and is headquartered in Brisbane, California.
Emergent BioSolutions, Inc. closed at $6.93 up $1.94 (38.88%) with volume of 1,679,761 Emergent BioSolutions Inc. (NYSE: EBS - News) announced yesterday that the final analysis from a recently completed, randomized, placebo-controlled, blinded Phase II clinical study reaffirmed that its single-dose, drinkable typhoid vaccine candidate was highly immunogenic and well-tolerated with an acceptable safety profile in the population studied. For the study, a total of 151 Vietnamese children between 5 and 14 years of age were enrolled. A total of 101 children received the vaccine candidate and 50 children received placebo. This clinical study is the first trial involving a pediatric population and was performed in collaboration with the Wellcome Trust, Oxford University and the Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.
About Emergent BioSolutions, Inc.
Emergent BioSolutions, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of immunobiotics primarily in the United States. Immunobiotics are pharmaceutical products, such as vaccines and immune globulins that assist the body's immune system to prevent diseases. The company operates in two segments, Biodefense and Commercial. The Biodefense segment develops, manufactures, and commercializes immunobiotics for use against biological agents. This segment's primary product is BioThrax, a vaccine for the prevention of anthrax infection. Its other products, which are in preclinical stage comprise Anthrax immune globulin, for post-exposure treatment of anthrax infection; Botulinum immune globulin for post-exposure treatment of illness caused by botulinum toxin; and Recombinant bivalent botulinum vaccine, a prophylaxis for illness caused by botulinum toxin. The Commercial segment develops immunobiotics for use against infectious diseases. This segment's product portfolio includes Typhoid vaccine, a single-dose vaccine in phase II clinical development; Hepatitis B therapeutic vaccine, for treating chronic carriers of hepatitis B infection, which is in phase II clinical development; and Group B streptococcus vaccine, a product in phase I clinical trial for administration to women of childbearing age for protection of the fetus and newborn babies. In addition, Emergent BioSolutions is developing a chlamydia vaccine and a meningitis B vaccine, which are in preclinical development. The company serves primarily the U.S. Department of Defense and the U.S. Department of Health and Human Services. It has collaboration agreements with U.K. Health Protection Agency for the development of a human botulinum immune globulin candidate; and with Sanofi Pasteur for the development of meningitis B vaccine candidate. The company, formerly known as BioPort Corporation, was founded in 1998 and is based in Rockville, Maryland.
Krispy Kreme Doughnuts, Inc. closed at $3.15 up $.32 (11.31%) with volume of 2,482,662 Krispy Kreme Doughnuts, Inc. (NYSE: KKD - News) announced yesterday that all Krispy Kreme products sold in the United States have zero grams trans fat. "Krispy Kreme's Research and Development team has worked diligently for quite some time to offer zero grams trans fat products that deliver the one-of-a-kind Krispy Kreme taste that people have loved for generations," said Stan Parker, Krispy Kreme's Senior Vice President of Marketing. "We've been piloting zero grams trans fat products across the country for the past several months and have received an overwhelmingly positive response." About Krispy Kreme Doughnuts, Inc.
Krispy Kreme Doughnuts, Inc. operates as a branded retailer and wholesaler of doughnuts. It engages in the ownership and franchising of Krispy Kreme doughnut stores, which make and sell approximately 20 varieties of doughnuts. These stores also offer an array of coffees and other beverages. As of January 28, 2007, there were 395 Krispy Kreme stores operated system wide in 40 states in the United States, Australia, Canada, Hong Kong, Indonesia, Japan, Kuwait, Mexico, the Philippines, South Korea, and the United Kingdom, of which 113 were owned by the company and 282 were owned by franchisees. The company was founded in 1937 and is headquartered in Winston-Salem, North Carolina.
Pharmasset, Inc. closed at $20.24 up $6.25 (44.67%) with volume of 1,228,111 Pharmasset, Inc. (Nasdaq: VRUS - News) announced yesterday the preliminary results of a 4-week Phase 1 clinical trial to evaluate two oral dose levels of R7128 in combination with Pegasys (pegylated interferon) plus Copegus (ribavirin) in 50 treatment-naive patients chronically infected with hepatitis C virus (HCV) genotype 1. In this study, R7128 demonstrated potent short-term antiviral activity and was generally safe and well-tolerated. Eighty-five (85%) of patients receiving R7128 1500mg and Pegasys plus Copegus achieved undetectable HCV RNA levels following 4 weeks of treatment with safety and tolerability comparable to placebo. R7128 is a prodrug of PSI-6130, a cytidine nucleoside analogue polymerase inhibitor of HCV that is being developed through Pharmasset's collaboration with Roche.
About Pharmasset, Inc.
Pharmasset, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of drugs to treat viral infections. It focuses on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). The company focuses on three product candidates: Clevudine, an oral pyrimidine nucleoside analog, for the treatment of HBV, which is entering the United States and European Phase III registration clinical trials, and is approved for HBV in South Korea and marketed by Bukwang Pharm. Co., Ltd. under the brand name Levovir; R7128, an oral pro-drug of PSI-6130 for the treatment of HCV, that is in a Phase 1 clinical trial through a strategic collaboration with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; and Racivir for the treatment of HIV in combination with other approved HIV drugs that is in a Phase 2 clinical trial. It also engages in the discovery and development of additional antiviral therapeutics using nucleoside chemistry. Pharmasset was founded in 1998 as Pharmasset, Ltd. and changed its name to Pharmasset, Inc. in 2004. The company is headquartered in Princeton, New Jersey.
About Emerging Markets Consulting, LLC Emerging Markets Consulting, LLC is an investor relations and consulting firm serving carefully selected micro cap and small cap clients. Services available include turnkey investor relations services, consulting, marketing and related services needed by publicly traded companies. EMC is unique in that they only work with companies after a stringent due diligence process and they also work with a limited number of clients in order to provide service that is exceptional. The above referenced companies are not clients of Emerging Markets and no compensation has been paid for the exposure provided by this report.
Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned. Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. Reproduction without written permission is prohibited.
Please remember to go to www.emergingmarketsllc.com and enter your email address to sign up for our free newsletter.
CONTACT: Emerging Markets Consulting, LLC Tel: +1 321 206 6682 e-mail: jamespainter@emergingmarketsllc.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
|
|
